Michael Milken, 60,000 Deaths, and the Story of Dendreon (Chapter 5 of 15) 29 June 2009 by Mark Mitchell In the latest chapter of this drama, CNBC's Jim Cramer makes "a mistake" -- again! --...
opinion by RoryKearney | 22 wks ago | updated 20 wks ago 2715 views | 14 recommendations | 5 comments
Scientists at the Campbell Family Institute for Breast Cancer Research in Toronto have combined a naturally occuring component of the immune system with a viral vaccine. The result boosted the body's immunity...
Tomorrow, April 28, 2009, at long last the day of reckoning for Immunotherapy is upon us. Dendreon will present its statistically significant Impact trial results on Provenge at the American Urological...
opinion by RoryKearney | 30 wks ago | updated 30 wks ago 1267 views | 20 recommendations | 0 comments
A non toxic, non invasive Immunotherapy to strengthen the body’s ability to fight prostate cancer achieved its goal of being supportive of the previous trials, as required by the FDA. Mitchell Gold,...
opinion by RoryKearney | 31 wks ago | updated 31 wks ago 648 views | 43 recommendations | 11 comments
The Wick Family has 4 men with prostate cancer. Too late. Make that 3. Brad's Uncle died this week. If Provenge were approved 2 years ago, as it should have been, he might still be with us today. With...
opinion by RoryKearney | 38 wks ago | updated 38 wks ago 554 views | 10 recommendations | 1 comment
Just when you thought it was safe, once again our Government proves it is one big revolving bed. Once again "we the people" are just an annoyance to the power elite. Who cares what we think and need. They will do...
opinion by RoryKearney | 38 wks ago | updated 38 wks ago 505 views | 12 recommendations | 2 comments
""Based upon its impressive capabilities, we believe MaxCyte's cell loading technology can be an important component of our closed system," said Baek Chun Lee, Ph.D., Binex's Chairman. "Our immunotherapy product is currently undergoing review by the Korean FDA for colorectal...
created by uusjio | 1 year ago 252 views | 0 recommendations | 0 comments